Page last updated: 2024-12-05

4-deoxypyridoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-deoxypyridoxine: RN given refers to parent cpd; structure; pyridoxine antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-deoxypyridoxine : A pyridine ring substituted with methyl groups at positions 2 and 4, a hydroxyl at position 3, and a hydroxymethyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6094
CHEMBL ID3244689
CHEBI ID65083
SCHEMBL ID1049253
MeSH IDM0045815

Synonyms (29)

Synonym
.alpha.4-norpyridoxine
5-hydroxymethyl-2,4-dimethyl-pyridin-3-ol
4-deoxypyridoxine
5-hydroxy-4,6-dimethyl-3-pyridinemethanol
deoxypyridoxine
4-desoxypyridoxine
desoxypyridoxine
brn 0128029
3-pyridinemethanol, 4,6-dimethyl-5-hydroxy-
4-deoxypyridoxol
3-pyridinemethanol, 5-hydroxy-4,6-dimethyl-
61-67-6
5-(hydroxymethyl)-2,4-dimethyl-pyridin-3-ol
5-(hydroxymethyl)-2,4-dimethylpyridin-3-ol
AKOS006228872
unii-b7lkf6jmq3
b7lkf6jmq3 ,
4-deoxypyridoxal
CHEBI:65083 ,
CHEMBL3244689
SCHEMBL1049253
KKOWAYISKWGDBG-UHFFFAOYSA-N
5-(hydroxymethyl)-2,4-dimethyl-3-pyridinol #
adermine, 4-deoxy-
DTXSID50209849
2,4-dimethyl-3-hydroxy-5-hydroxymethylpyridin
Q4637123
SB55127
5-hydroxymethyl-2,4-dimethylpyridin-3-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
hydroxymethylpyridineAny member of the class of pyridines carrying a hydroxymethyl substituent at unspecified position.
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1147925Inhibition of pyridoxine phosphate oxidase in mouse TA3 cells assessed as inhibition of 10'-5 M pyridoxal-induced cell growth1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
4-Halovinyl- and 4-ethynyl-4-deformylpyridoxal derivatives and related analogues as potentially irreversible antagonists of vitamin B6.
AID1131373Growth inhibition of mouse TA3 cells after 3 days incubation in presence of 10'-7 M pyridoxal1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Antagonists of vitamin B6. Simultaneous and stepwise modification of the 2 and 4 positions.
AID1131375Growth inhibition of mouse TA3 cells after 3 days incubation in presence of 10'-5 M pyridoxal1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Antagonists of vitamin B6. Simultaneous and stepwise modification of the 2 and 4 positions.
AID1147924Inhibition of pyridoxine phosphate oxidase in mouse TA3 cells assessed as inhibition of 1 x 10'-7 M pyridoxal-induced cell growth1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
4-Halovinyl- and 4-ethynyl-4-deformylpyridoxal derivatives and related analogues as potentially irreversible antagonists of vitamin B6.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (64.71)18.7374
1990's10 (19.61)18.2507
2000's4 (7.84)29.6817
2010's3 (5.88)24.3611
2020's1 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.39 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index27.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (98.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]